RenovoRx gets USPTO notice of allowance for new RenovoCath cancer drug-delivery patent

RNXT•2026-08-20

USPTO notice of allowance for RenovoCath patent

RenovoRx received a USPTO notice of allowance for a new U.S. patent application covering its RenovoCath dual-occlusion cancer drug-delivery catheter.

The application, titled “Methods and Apparatuses for Delivery of Therapeutic Materials for the Treatment of Cancer,” is expected to expand protection for TAMP.

RenovoRx said its global IP portfolio now totals 20 issued or allowed patents, with 13 additional patents pending.

RenovoRx gets USPTO notice of allowance for new RenovoCath cancer drug-delivery patent

USPTO notice of allowance for RenovoCath patent

Related News

BullFrog AI gets Nasdaq extension to regain $1 minimum bid compliance, avoids delisting until Feb. 8, 2027

Artelo Biosciences wins Japan patent allowance for ART27.13 commercial formulation

Nomadar Announces Strategic Partnership With New Hera Interconnection To Develop Joint Sports Programs Between Usa, Europe And Africa

Better Home & Finance Holding Company Adopts Limited-Duration Shareholder Rights Plan

BofA lowers Henry forecast to $3.35/MMBtu for 4Q26, $3.65 for 2027, on weak N. America LNG feedgas demand and record gas production